Join
Live feed
·
PRReleasevia Quantisnow
Apogee Therapeutics Inc. logo

Apogee Therapeutics to Host Conference Call to Report Interim Results from the Phase 1b Trial of APG777 in Patients with Mild-to-Moderate Asthma and 2026 Anticipated Milestones on January 6, 2026

ByQuantisnow·Wall Street's wire, on your screen.
APGE· Apogee Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track APGE (Apogee Therapeutics Inc.) and more on Quantisnow.